Skip to main content
Top
Published in: Pediatric Rheumatology 1/2019

Open Access 01-12-2019 | Kawasaki Disease | Research article

The role of age-specific N-terminal pro-brain natriuretic peptide cutoff values in predicting intravenous immunoglobulin resistance in Kawasaki disease: a prospective cohort study

Authors: Shuran Shao, Chunyan Luo, Kaiyu Zhou, Yimin Hua, Mei Wu, Lei Liu, Xiaoliang Liu, Chuan Wang

Published in: Pediatric Rheumatology | Issue 1/2019

Login to get access

Abstract

Background

The prediction of resistance to intravenous immunoglobulins (IVIG) is currently still one of the main research areas in Kawasaki disease (KD). Several studies have reported on the use of N-terminal pro-brain natriuretic peptide (NT-ProBNP) to this end. However, considering the age-dependency of NT-ProBNP levels, age- specific NT-ProBNP cutoff levels to predict IVIG resistance in KD might be more precise and should be evaluated.

Methods

A prospective cohort study with standardized data collection involving 393 KD patients aged 1 month to 125 months was conducted between June 2015 and April 2018. The demographic characteristics, clinical manifestations and laboratory data were compared between the patients responding to initial intravenous immunoglobulin (IVIG-response group) and those who did not (IVIG-resistance group). We further distinguished four subgroups according to patients’ age (< 1 year, 1–2 years, 2–6 years, > 6 years). The cutoff values of NT-ProBNP for the prediction of IVIG resistance overall and in the subgroups were obtained using receiver operating characteristic (ROC) analysis.

Results

In all KD patients, the level of NT-ProBNP was significantly higher in the IVIG-resistance compared to the IVIG-response group (P = 0.006). This findings was similar in the subgroups except for patients older than six years. The best cutoff values of NT-ProBNP to predict IVIG resistance were 3755 pg/ml for all KD patients, 3710 pg/ml, 2800 pg/ml, 2480 pg/ml for those aged 2–6 years, 1–2 years and < 1 year, respectively. The corresponding sensitivities were 44.0, 52.2, 50.0 and 75.0%, while the specifities were 84.1, 86.3, 77.9 and 71.8%, respectively.

Conclusions

NT-proBNP is a complementary laboratory marker for the prediction of IVIG resistance in KD patients, particularly for those younger than one year. Applying age-specific cutoff values is more precise than one value for all ages.
Appendix
Available only for authorised users
Literature
1.
go back to reference Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J. 2008;27(2):155.PubMed Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J. 2008;27(2):155.PubMed
2.
go back to reference Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613–20.CrossRef Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613–20.CrossRef
3.
go back to reference Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–8.CrossRef Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–8.CrossRef
4.
go back to reference Maggio MC, Cimaz R, Alaimo A, Comparato C, Di Lisi D, Corsello G. Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings. J Med Case Rep. 2019;13(1):104.CrossRef Maggio MC, Cimaz R, Alaimo A, Comparato C, Di Lisi D, Corsello G. Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings. J Med Case Rep. 2019;13(1):104.CrossRef
5.
go back to reference Kone-Paut I, Cimaz R, Herberg J, Bates O, Carbasse A, Saulnier JP, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun Rev. 2018;17(8):768–74.CrossRef Kone-Paut I, Cimaz R, Herberg J, Bates O, Carbasse A, Saulnier JP, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun Rev. 2018;17(8):768–74.CrossRef
6.
go back to reference Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019;393(10176):1128–37.CrossRef Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019;393(10176):1128–37.CrossRef
7.
go back to reference Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol. 2009;30(6):810–7.CrossRef Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol. 2009;30(6):810–7.CrossRef
8.
go back to reference Lemos JA, De MDK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316–22.CrossRef Lemos JA, De MDK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316–22.CrossRef
9.
go back to reference Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88(1):82–91.CrossRef Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88(1):82–91.CrossRef
10.
go back to reference Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, et al. Association of Multiple Biomarkers with Risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker study. JAMA Cardiol. 2018;3(12):1160–6.CrossRef Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, et al. Association of Multiple Biomarkers with Risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker study. JAMA Cardiol. 2018;3(12):1160–6.CrossRef
11.
go back to reference Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, et al. Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. J Am Heart Assoc. 2017;6(6). Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, et al. Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. J Am Heart Assoc. 2017;6(6).
12.
go back to reference Brozaitiene J, Mickuviene N, Podlipskyte A, Burkauskas J, Bunevicius R. Relationship and prognostic importance of thyroid hormone and N-terminal pro-B-type natriuretic peptide for patients after acute coronary syndromes: a longitudinal observational study. BMC Cardiovasc Disord. 2016;16:45.CrossRef Brozaitiene J, Mickuviene N, Podlipskyte A, Burkauskas J, Bunevicius R. Relationship and prognostic importance of thyroid hormone and N-terminal pro-B-type natriuretic peptide for patients after acute coronary syndromes: a longitudinal observational study. BMC Cardiovasc Disord. 2016;16:45.CrossRef
13.
go back to reference Siva Sankara C, Rajasekhar D, Vanajakshamma V, Praveen Kumar BS, Vamsidhar A. Prognostic significance of NT-proBNP, 3D LA volume and LV dyssynchrony in patients with acute STEMI undergoing primary percutaneous intervention. Indian Heart J. 2015;67(4):318–27.CrossRef Siva Sankara C, Rajasekhar D, Vanajakshamma V, Praveen Kumar BS, Vamsidhar A. Prognostic significance of NT-proBNP, 3D LA volume and LV dyssynchrony in patients with acute STEMI undergoing primary percutaneous intervention. Indian Heart J. 2015;67(4):318–27.CrossRef
14.
go back to reference Kim SY, Han MY, Cha SH, Jeon YB. N-terminal pro-brain natriuretic peptide (NT proBNP) as a predictive indicator of initial intravenous immunoglobulin treatment failure in children with Kawasaki disease: a retrospective study. Pediatr Cardiol. 2013;34(8):1837–43.CrossRef Kim SY, Han MY, Cha SH, Jeon YB. N-terminal pro-brain natriuretic peptide (NT proBNP) as a predictive indicator of initial intravenous immunoglobulin treatment failure in children with Kawasaki disease: a retrospective study. Pediatr Cardiol. 2013;34(8):1837–43.CrossRef
15.
go back to reference Kim HK, Oh J, Hong YM, Sohn S. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in Kawasaki disease. Korean Circ J. 2011;41(7):379–84.CrossRef Kim HK, Oh J, Hong YM, Sohn S. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in Kawasaki disease. Korean Circ J. 2011;41(7):379–84.CrossRef
16.
go back to reference Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease. J Pediatr. 2013;162(6):1205–9.CrossRef Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease. J Pediatr. 2013;162(6):1205–9.CrossRef
17.
go back to reference Lee HY, Song MS. Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease. Korean J Pediatr. 2016;59(12):477–82.CrossRef Lee HY, Song MS. Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease. Korean J Pediatr. 2016;59(12):477–82.CrossRef
18.
go back to reference Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol. 2009;30(1):3–8.CrossRef Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol. 2009;30(1):3–8.CrossRef
19.
go back to reference Lin CW, Zeng XL, Zhang JF, Meng XH. Determining the optimal cutoff values of plasma N-terminal pro-B-type natriuretic peptide levels for the diagnosis of heart failure in children of age up to 14 years. J Card Fail. 2014;20(3):168–73.CrossRef Lin CW, Zeng XL, Zhang JF, Meng XH. Determining the optimal cutoff values of plasma N-terminal pro-B-type natriuretic peptide levels for the diagnosis of heart failure in children of age up to 14 years. J Card Fail. 2014;20(3):168–73.CrossRef
20.
go back to reference Li S, Xiao Z, Li L, Hu B, Zhou Z, Yi S, et al. Establishment of normal reference values of NT-proBNP and its application in diagnosing acute heart failure in children with severe hand food and mouth disease. Medicine (Baltimore). 2018;97(36):e12218.CrossRef Li S, Xiao Z, Li L, Hu B, Zhou Z, Yi S, et al. Establishment of normal reference values of NT-proBNP and its application in diagnosing acute heart failure in children with severe hand food and mouth disease. Medicine (Baltimore). 2018;97(36):e12218.CrossRef
21.
go back to reference Schwachtgen L, Herrmann M, Georg T, Schwarz P, Marx N, Lindinger A. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol. 2005;94(6):399–404.CrossRef Schwachtgen L, Herrmann M, Georg T, Schwarz P, Marx N, Lindinger A. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol. 2005;94(6):399–404.CrossRef
22.
go back to reference Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics. 2004;114(6):1708–33.CrossRef Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics. 2004;114(6):1708–33.CrossRef
23.
go back to reference Arjunan K, Daniels SR, Meyer RA, Schwartz DC, Barron H, Kaplan S. Coronary artery caliber in normal children and patients with Kawasaki disease but without aneurysms: an echocardiographic and angiographic study. J Am Coll Cardiol. 1986;8(5):1119–24.CrossRef Arjunan K, Daniels SR, Meyer RA, Schwartz DC, Barron H, Kaplan S. Coronary artery caliber in normal children and patients with Kawasaki disease but without aneurysms: an echocardiographic and angiographic study. J Am Coll Cardiol. 1986;8(5):1119–24.CrossRef
24.
go back to reference Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glode MP, Dominguez SR. Infliximab plus intravenous immunoglobulin (IVIG) versus IVIG alone as initial therapy in children with Kawasaki disease presenting with coronary artery lesions: is dual therapy more effective? Pediatr Infect Dis J. 2018;37(10):976–80.CrossRef Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glode MP, Dominguez SR. Infliximab plus intravenous immunoglobulin (IVIG) versus IVIG alone as initial therapy in children with Kawasaki disease presenting with coronary artery lesions: is dual therapy more effective? Pediatr Infect Dis J. 2018;37(10):976–80.CrossRef
25.
go back to reference Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–12.CrossRef Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–12.CrossRef
26.
go back to reference Lin MT, Chang CH, Sun LC, Liu HM, Chang HW, Chen CA, et al. Risk factors and derived Formosa score forintravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease. J Formos Med Assoc. 2016;115(5):350–5.CrossRef Lin MT, Chang CH, Sun LC, Liu HM, Chang HW, Chen CA, et al. Risk factors and derived Formosa score forintravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease. J Formos Med Assoc. 2016;115(5):350–5.CrossRef
27.
go back to reference Yang S, Song R, Zhang J, Li X, Li C. Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing. Arch Dis Child. 2019;104(3):262–7.CrossRef Yang S, Song R, Zhang J, Li X, Li C. Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing. Arch Dis Child. 2019;104(3):262–7.CrossRef
28.
go back to reference Tang Y, Yan W, Sun L, Huang J, Qian W, Ding Y, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population. Clin Rheumatol. 2016;35(11):2771–6.CrossRef Tang Y, Yan W, Sun L, Huang J, Qian W, Ding Y, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population. Clin Rheumatol. 2016;35(11):2771–6.CrossRef
29.
go back to reference Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–40.CrossRef Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–40.CrossRef
30.
go back to reference Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–7.CrossRef Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–7.CrossRef
31.
go back to reference Hua W, Sun Y, Wang Y, Fu S, Wang W, Xie C, et al. A new model to predict intravenous immunoglobin-resistant Kawasaki disease. Oncotarget. 2017;8(46):80722–9.CrossRef Hua W, Sun Y, Wang Y, Fu S, Wang W, Xie C, et al. A new model to predict intravenous immunoglobin-resistant Kawasaki disease. Oncotarget. 2017;8(46):80722–9.CrossRef
32.
go back to reference Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831–5.e3.CrossRef Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831–5.e3.CrossRef
33.
go back to reference Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E. Role of the Egami score in predicting intravenous immunoglobulin resistance in Kawasaki disease among different ethnicities. Am J Ther. 2016;23(6):e1293–e9.CrossRef Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E. Role of the Egami score in predicting intravenous immunoglobulin resistance in Kawasaki disease among different ethnicities. Am J Ther. 2016;23(6):e1293–e9.CrossRef
34.
go back to reference Kim BY, Kim D, Kim YH, Ryoo E, Sun YH, Jeon IS, et al. Non-responders to intravenous immunoglobulin and coronary artery dilatation in Kawasaki disease: predictive parameters in Korean children. Korean Circ J. 2016;46(4):542–9.CrossRef Kim BY, Kim D, Kim YH, Ryoo E, Sun YH, Jeon IS, et al. Non-responders to intravenous immunoglobulin and coronary artery dilatation in Kawasaki disease: predictive parameters in Korean children. Korean Circ J. 2016;46(4):542–9.CrossRef
35.
go back to reference Jakob A, von Kries R, Horstmann J, Hufnagel M, Stiller B, Berner R, et al. Failure to predict high-risk Kawasaki disease patients in a population-based study cohort in Germany. Pediatr Infect Dis J. 2018;37(9):850–5.CrossRef Jakob A, von Kries R, Horstmann J, Hufnagel M, Stiller B, Berner R, et al. Failure to predict high-risk Kawasaki disease patients in a population-based study cohort in Germany. Pediatr Infect Dis J. 2018;37(9):850–5.CrossRef
36.
go back to reference Sanchez-Manubens J, Anton J, Bou R, Iglesias E, Calzada-Hernandez J, Borlan S, et al. Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population. Rheumatol Int. 2016;36(7):905–10.CrossRef Sanchez-Manubens J, Anton J, Bou R, Iglesias E, Calzada-Hernandez J, Borlan S, et al. Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population. Rheumatol Int. 2016;36(7):905–10.CrossRef
37.
go back to reference Song R, Yao W, Li X. Efficacy of four scoring Systems in Predicting Intravenous Immunoglobulin Resistance in children with Kawasaki disease in a Children's Hospital in Beijing, North China. J Pediatr. 2017;184:120–4.CrossRef Song R, Yao W, Li X. Efficacy of four scoring Systems in Predicting Intravenous Immunoglobulin Resistance in children with Kawasaki disease in a Children's Hospital in Beijing, North China. J Pediatr. 2017;184:120–4.CrossRef
38.
go back to reference Qian W, Tang Y, Yan W, Sun L, Lv H. A comparison of efficacy of six prediction models for intravenous immunoglobulin resistance in Kawasaki disease. Ital J Pediatr. 2018;44(1):33.CrossRef Qian W, Tang Y, Yan W, Sun L, Lv H. A comparison of efficacy of six prediction models for intravenous immunoglobulin resistance in Kawasaki disease. Ital J Pediatr. 2018;44(1):33.CrossRef
39.
go back to reference Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med. 2004;42(8):965–72.CrossRef Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med. 2004;42(8):965–72.CrossRef
40.
go back to reference Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail. 2004;6(3):365–8.CrossRef Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail. 2004;6(3):365–8.CrossRef
Metadata
Title
The role of age-specific N-terminal pro-brain natriuretic peptide cutoff values in predicting intravenous immunoglobulin resistance in Kawasaki disease: a prospective cohort study
Authors
Shuran Shao
Chunyan Luo
Kaiyu Zhou
Yimin Hua
Mei Wu
Lei Liu
Xiaoliang Liu
Chuan Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2019
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-019-0368-8

Other articles of this Issue 1/2019

Pediatric Rheumatology 1/2019 Go to the issue